Rate Notice: 5.9% general rate increase Jan 1, 2026 — Learn More
    ZHO

    Zhong Wenyan

    Zhong Wenyan is a leading oncology data scientist at AstraZeneca, specializing in pan-cancer proteomics and cancer therapeutic target discovery.

    Company Overview

    Zhong Wenyan operates within the pharmaceutical and biotechnology sector, focusing on oncology data science and proteomics research. Based at AstraZeneca, the company is involved in advanced cancer research, leveraging large-scale proteomics data to identify novel therapeutic targets. Their work supports the development of innovative cancer treatments and precision medicine.

    Key Metrics

    N/A

    Import Shipments

    8

    Distribution Centers

    2.5B

    Annual Revenue

    1999

    Founded

    Company Profile

    Key Milestones

    Important company milestones and achievements.

    Markets Served

    Geographic markets and customer segments served.

    Ownership Structure

    Corporate ownership and organizational structure.

    Sales Channels

    Distribution networks and sales approaches.

    Recent Developments

    Recent activities focus on integrating advanced proteomics data and AI-driven analytics to accelerate cancer therapeutic discovery.

    Strategic Expansion

    Adoption of intensity-based absolute quantification (iBAQ) for improved protein analysis

    Market Expansion

    Strategic efforts to expand market presence and reach new customer segments.

    Technology Adoption

    Implementation of advanced technologies to improve service delivery and customer experience.

    Business Information

    Zhong Wenyan is affiliated with AstraZeneca’s Oncology Data Science division, contributing to groundbreaking research in cancer proteomics. The company utilizes multiplex mass spectrometry and advanced computational approaches to analyze tumor-enriched cell surface antigens, supporting the development of antibody-drug conjugates and immunotherapeutic agents. Their research is integral to the Clinical Proteomic Tumor Analysis Consortium (CPTAC), providing valuable resources for cancer target discovery. AstraZeneca’s global infrastructure enables large-scale data integration and collaborative research across multiple international sites.

    Headquarters

    New York, New York, USA

    Founded

    1999

    Stock Symbol

    AZN